<html>
<head>
    <script language="JavaScript" src="http://code.jquery.com/jquery-1.4.4.js"></script>
    <script language="JavaScript" src="../js/pie.js"></script>
    <script language="JavaScript" src="../js/browser_adjust.js"></script>
    <script language="JavaScript" src="../js/search.js"></script>


    <script type="text/JavaScript">
    <!--

    var array = [[15.9528330852, "../topics/{product,_candidate,_development}.html", "{product,_candidate,_development}"], [5.8149291897, "../topics/{property,_intellectual,_protect}.html", "{property,_intellectual,_protect}"], [4.4316909801, "../topics/{competitive,_industry,_competition}.html", "{competitive,_industry,_competition}"], [4.4145575184, "../topics/{acquisition,_growth,_future}.html", "{acquisition,_growth,_future}"], [3.9223969991, "../topics/{product,_liability,_claim}.html", "{product,_liability,_claim}"], [3.3991223318, "../topics/{financial,_litigation,_operation}.html", "{financial,_litigation,_operation}"], [2.3512905304, "../topics/{stock,_price,_share}.html", "{stock,_price,_share}"], [1.7625161898, "../topics/{control,_financial,_internal}.html", "{control,_financial,_internal}"], [1.7450861365, "../topics/{cost,_regulation,_environmental}.html", "{cost,_regulation,_environmental}"], [1.7151738676, "../topics/{personnel,_key,_retain}.html", "{personnel,_key,_retain}"], [1.7139696728, "../topics/{cost,_contract,_operation}.html", "{cost,_contract,_operation}"], [1.7099776732, "../topics/{debt,_indebtedness,_cash}.html", "{debt,_indebtedness,_cash}"], [1.7083593347, "../topics/{tax,_income,_asset}.html", "{tax,_income,_asset}"]];
    var elements = generate_pie_elements(array);
    var piec = null;
    function init() {
        browser_adjust();
        
        // create pie chart
        piec = new PieChart(elements);
        piec.initialize();

    }

    function highlight(i) {
        piec.highlight(i);
    }
    
    function unhighlight() {
        piec.unhighlight();
    }
    //-->
    </script>

    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    
    <title>716646--6/15/2009--CLINICAL_DATA_INC</title>

    <link href="../styling.css" rel="stylesheet" type="text/css">
</head>

<body onLoad="init()">
<div id="navigation">
<hr noshade>
<table><tr>
    <td class="navtext">Browse&nbsp;&#x25B8;</td> 
    <td class="linked"><a>Topics</a>
      <ul> 
        <li><a href="../browse/topic-list.html">List of Terms</a></li> 
        <li><a href="../browse/topic-graph.html">Term Distributions</a></li> 
        <li><a href="../browse/topic-presence.html">Relative Presence</a></li>
      </ul> 
    </td> 
    <td class="linked"><a>Documents</a>
      <ul>
        <li><a href="../browse/doc-graph.html">Topic Distributions</a></li>
      </ul> 
    </td>
    <td class="linked"><a>Terms</a>
      <ul> 
        <li><a href="../browse/term-list.html">List by Frequency</a></li> 
        <li><a href="../browse/term-graph.html">Topic Distributions</a></li> 
       </ul> 
    </td>
    <td class="linked"><a>About</a>
      <ul>
        <li><a href="http://www.cs.princeton.edu/~blei/lda-c/">LDA</a></li>
      </ul> 
    </td>
    
    </td>
    <td></td>
    <td class="searchbar"> Search&nbsp;&#x25B8;</td>
    <td class="searchbar"><input type="text" name="search" size="20" onkeypress="handleKeyPress(event)"><span onclick="doSearch()"></span>
    </td>
</tr></table>
</div>

    <div id="top"></div>

    <h1 id="header">
        <table><tr>
            <td id="title">716646--6/15/2009--CLINICAL_DATA_INC</td>
        </tr></table>

        <hr noshade>
    </h1>

    <div id="main">
        <table><tr>
            <td width="210px">
                <table class="dark">
                <tr><td><canvas id="canvas" width="200" height="200"></canvas></td></tr>
                <tr class="title">
                    <td>related topics</td>
                </tr>
                <tr class="list"><td id="{product,_candidate,_development}" onmouseover="highlight(0)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_candidate,_development}.html'">{product, candidate, development}</td></tr>
<tr class="list"><td id="{property,_intellectual,_protect}" onmouseover="highlight(1)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{property,_intellectual,_protect}.html'">{property, intellectual, protect}</td></tr>
<tr class="list"><td id="{competitive,_industry,_competition}" onmouseover="highlight(2)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{competitive,_industry,_competition}.html'">{competitive, industry, competition}</td></tr>
<tr class="list"><td id="{acquisition,_growth,_future}" onmouseover="highlight(3)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{acquisition,_growth,_future}.html'">{acquisition, growth, future}</td></tr>
<tr class="list"><td id="{product,_liability,_claim}" onmouseover="highlight(4)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{product,_liability,_claim}.html'">{product, liability, claim}</td></tr>
<tr class="list"><td id="{financial,_litigation,_operation}" onmouseover="highlight(5)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{financial,_litigation,_operation}.html'">{financial, litigation, operation}</td></tr>
<tr class="list"><td id="{stock,_price,_share}" onmouseover="highlight(6)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{stock,_price,_share}.html'">{stock, price, share}</td></tr>
<tr class="list"><td id="{control,_financial,_internal}" onmouseover="highlight(7)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{control,_financial,_internal}.html'">{control, financial, internal}</td></tr>
<tr class="list"><td id="{cost,_regulation,_environmental}" onmouseover="highlight(8)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_regulation,_environmental}.html'">{cost, regulation, environmental}</td></tr>
<tr class="list"><td id="{personnel,_key,_retain}" onmouseover="highlight(9)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{personnel,_key,_retain}.html'">{personnel, key, retain}</td></tr>
<tr class="list"><td id="{cost,_contract,_operation}" onmouseover="highlight(10)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{cost,_contract,_operation}.html'">{cost, contract, operation}</td></tr>
<tr class="list"><td id="{debt,_indebtedness,_cash}" onmouseover="highlight(11)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{debt,_indebtedness,_cash}.html'">{debt, indebtedness, cash}</td></tr>
<tr class="list"><td id="{tax,_income,_asset}" onmouseover="highlight(12)" onmouseout="unhighlight()" onclick="window.location.href='../topics/{tax,_income,_asset}.html'">{tax, income, asset}</td></tr>

                </table>
            </td>

            <td>
                <table class="light">
                <tr class="doc"><td>
                    Given our current product development efforts which have resulted in significant net losses, we expect to incur net losses for the foreseeable future.
If regulatory authorities fail to timely approve vilazodone for marketing, our results of operations will suffer.
Personalized medicine and pharmacogenomics is an emerging field, and therefore regulatory approval of our drug candidates that are paired with a companion diagnostic and diagnostic tests may take longer and be less predictable than approval for untargeted medicines.
If our assumption about the role of genes in diseases or drug response is wrong, we may not be able to develop useful products.
We may not successfully develop or derive revenues from any products.
We may not derive significant revenues from our diagnostic tests.
If physicians and patients do not accept and use our tests and drugs, we will not achieve sufficient product revenues and our business will suffer.
If our products are not granted adequate reimbursement from third-party payers, we may be unable to successfully commercialize our products and we may never achieve widespread market acceptance of our products.
We recently have entered into new business areas and may not have the expertise, experience and resources to pursue all of our businesses at once.
If we are unable to develop and/or in-license or otherwise acquire new products and technologies, we may not be able to grow our company successfully.
Due to our recent acquisitions and dispositions, it may be more difficult to obtain additional financing at favorable terms, if at all.
Because a significant portion of our total assets are represented by goodwill that is subject to mandatory annual impairment evaluations, we could be required to write-off some or all of this goodwill which may adversely affect our financial condition and results of operations.
We may be unable to successfully complete the integration of the businesses of Adenosine Therapeutics and Avalon.
We may not be able to successfully integrate companies that we acquire in the future.
We are dependent upon certain key personnel.
In order to conduct clinical trials and to market our drugs, we will have to develop methods to produce these drugs using approved methods and at commercially viable rates.
If we cannot successfully form and maintain suitable arrangements with third parties for the manufacturing of the products we may develop, our ability to develop or deliver products may be impaired.
New drug and genetic and pharmacogenetic test development involves a lengthy and complex process, and we may be unable to commercialize any of the products we develop.
Our operations may be affected by unexpected problems frequently encountered in connection with the development and transition to other technologies and by the competitive environment in which we operate.
The covenants in the convertible notes restrict our financial and operational flexibility.
Risk Factors Relating to Our Intellectual Property
If we are unable to protect effectively our intellectual property, we may not be able to operate our business and third parties may use our technology, both of which would impair our ability to compete in our markets.
If third parties make or file claims of intellectual property infringement against us, or otherwise seek to establish their intellectual property rights, we may have to spend time and money in response and cease some of our operations.
Any patent protection we obtain for our products may not prevent marketing of similar competing products.
Any patents we obtain may be challenged by producers of generic drugs.
Patents pending may not issue.
We may be unable to achieve milestones contained in our licensing agreements and have our license revoked by our licensors.
Risk Factors Relating to Regulatory Matters
Pre-clinical and clinical trials are time consuming, expensive, and uncertain processes.
Even if our drug candidates obtain regulatory approval, we will be subject to on-going government regulation.
We have only limited experience in regulatory affairs which may affect our ability or the time we require to obtain necessary regulatory approvals.
Third parties engaged to produce our drug candidates for clinical use may fail to comply with regulatory requirements, which could harm our clinical trials.
Our operations involve hazardous materials and medical waste and are subject to environmental, health and safety controls and regulations Any claim relating to our improper handling, storage or disposal of biological and hazardous materials could be time-consuming and costly, and may exceed our resources.
Our business involves animal testing and changes in laws, regulations or accepted clinical procedures or social pressures could restrict our use of animals in testing and adversely affect our research and development efforts.
Risk Factors Relating to Our Industry
Concerns regarding the use of genetic testing results may limit the commercial viability of any products we develop.
If we were sued for product liability, we could face substantial liabilities that may exceed our resources.
We may not be able to compete successfully with other companies and government agencies in the development and marketing of products and services.
Intense competition could reduce our market share or limit our ability to increase market share, which could harm our financial performance.
We operate in a very competitive environment.
Risk Factors Relating to Our Common Stock
Future sales of our common stock or other securities may dilute our stockholders.
<p><a href="http://www.sec.gov/Archives/edgar/data/716646/0000950123-09-014096.txt">Full 10-K form&nbsp;&#x25B8;</a></p>
                </td></tr>
                </table>
            </td>

            <td width="25%">
                <table class="dark">
                <tr class="title">
                    <td>related documents</td>
                </tr>
                <tr class="list"><td onclick="window.location.href='../docs/716646--6-14-2010--CLINICAL_DATA_INC.html'">716646--6/14/2010--CLINICAL_DATA_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/901219--3-14-2006--HUMAN_GENOME_SCIENCES_INC.html'">901219--3/14/2006--HUMAN_GENOME_SCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1140028--4-2-2007--Hana_Biosciences_Inc.html'">1140028--4/2/2007--Hana_Biosciences_Inc</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/901219--2-26-2008--HUMAN_GENOME_SCIENCES_INC.html'">901219--2/26/2008--HUMAN_GENOME_SCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/901219--2-28-2007--HUMAN_GENOME_SCIENCES_INC.html'">901219--2/28/2007--HUMAN_GENOME_SCIENCES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1070336--3-27-2009--ACHILLION_PHARMACEUTICALS_INC.html'">1070336--3/27/2009--ACHILLION_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899460--3-16-2006--MANNKIND_CORP.html'">899460--3/16/2006--MANNKIND_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/879169--3-3-2009--INCYTE_CORP.html'">879169--3/3/2009--INCYTE_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899460--3-16-2007--MANNKIND_CORP.html'">899460--3/16/2007--MANNKIND_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899460--2-27-2009--MANNKIND_CORP.html'">899460--2/27/2009--MANNKIND_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1019695--3-17-2008--ARQULE_INC.html'">1019695--3/17/2008--ARQULE_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/899460--3-14-2008--MANNKIND_CORP.html'">899460--3/14/2008--MANNKIND_CORP</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1019695--3-6-2009--ARQULE_INC.html'">1019695--3/6/2009--ARQULE_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1107601--3-10-2006--ATHEROGENICS_INC.html'">1107601--3/10/2006--ATHEROGENICS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/911326--3-10-2006--TRIMERIS_INC.html'">911326--3/10/2006--TRIMERIS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/934473--3-16-2007--GENVEC_INC.html'">934473--3/16/2007--GENVEC_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1142380--3-31-2006--CALLISTO_PHARMACEUTICALS_INC.html'">1142380--3/31/2006--CALLISTO_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1142380--4-15-2009--CALLISTO_PHARMACEUTICALS_INC.html'">1142380--4/15/2009--CALLISTO_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1010086--3-6-2009--SIGA_TECHNOLOGIES_INC.html'">1010086--3/6/2009--SIGA_TECHNOLOGIES_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1142380--3-28-2008--CALLISTO_PHARMACEUTICALS_INC.html'">1142380--3/28/2008--CALLISTO_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1070494--3-15-2006--ACADIA_PHARMACEUTICALS_INC.html'">1070494--3/15/2006--ACADIA_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1128495--3-5-2008--ANADYS_PHARMACEUTICALS_INC.html'">1128495--3/5/2008--ANADYS_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1070494--3-9-2007--ACADIA_PHARMACEUTICALS_INC.html'">1070494--3/9/2007--ACADIA_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1142380--4-17-2007--CALLISTO_PHARMACEUTICALS_INC.html'">1142380--4/17/2007--CALLISTO_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/729922--3-16-2006--OSI_PHARMACEUTICALS_INC.html'">729922--3/16/2006--OSI_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/872589--2-28-2006--REGENERON_PHARMACEUTICALS_INC.html'">872589--2/28/2006--REGENERON_PHARMACEUTICALS_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1005201--3-12-2008--DEPOMED_INC.html'">1005201--3/12/2008--DEPOMED_INC</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/875320--3-1-2007--VERTEX_PHARMACEUTICALS_INC_-_MA.html'">875320--3/1/2007--VERTEX_PHARMACEUTICALS_INC_/_MA</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/906709--3-1-2007--NEKTAR_THERAPEUTICS.html'">906709--3/1/2007--NEKTAR_THERAPEUTICS</td></tr>
<tr class="list"><td onclick="window.location.href='../docs/1226616--3-17-2008--MEDICINOVA_INC.html'">1226616--3/17/2008--MEDICINOVA_INC</td></tr>

                </table>
            </td>
        </tr></table>
    </div>

    <div id="footer">
        <br>
        <hr noshade>
    </div>
</body>
</html>
